TB-500: A Fragment Carrying a Bigger Protein's Reputation

The short version

TB-500 is a small synthetic peptide — seven amino acids — with the sequence Ac-LKKTETQ. That sequence is the actin-binding piece of a larger natural protein called thymosin beta-4. Actin is part of the internal skeleton cells use to hold their shape and to migrate toward a wound, so the parent protein is tied to cell movement, healing, and new blood-vessel growth ^[8].

The single most important thing to understand about TB-500 is a naming gap. In commerce and in anti-doping labs, "TB-500" means the short seven-amino-acid fragment. But most published effectiveness research was done with the full-length protein, roughly five times larger ^[8]. It is not established that the small fragment reproduces what the whole protein does. TB-500 is not an approved medicine, it is banned in sport, and this page reports doses only as they were studied — never as advice.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide — seven amino acids with a small chemical cap on one end — with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. This LKKTETQ stretch corresponds to residues 17-23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein, and is the conserved actin-binding region of the beta-thymosin family.

The distinction matters throughout: the fragment sold and detected as TB-500 weighs about 889 daltons; full-length Tβ4 is about 4,963 daltons. Wherever a study below used the full protein rather than the 7-mer, this digest flags it, because that is exactly where TB-500 marketing borrows a larger molecule's evidence ^[8].

How it works

Full-length thymosin beta-4 is the body's major intracellular G-actin sequestering peptide. G-actin is the free single-unit form of actin; sequestering means Tβ4 grabs and holds those units so they are not assembled into filaments until needed. A 2-angstrom X-ray crystal structure of a gelsolin-Tβ4 hybrid bound to actin established that Tβ4 forms a 1:1 complex with G-actin and caps both ends of the monomer, preventing polymerization — the structural basis for its actin-buffering role ^[10].

By regulating the actin skeleton, Tβ4 (and the LKKTETQ motif it contains) is associated with faster cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, reduced scar-forming myofibroblasts, and progenitor-cell recruitment, consolidated across dermal-wound, corneal, cardiac and CNS models ^[8]. Whether the isolated seven-amino-acid fragment reproduces all of that at the doses used in peptide research has not been shown in controlled human trials ^[8].

What the research shows

Structural and mechanistic basis. X-ray crystallography pinned down the 1:1 actin-capping mechanism ^[10]. A multi-model review consolidated Tβ4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development in dermal wounds, corneal injury, and cardiac and CNS repair ^[8].

Cardiac repair. In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activating Akt; after coronary artery ligation it upregulated ILK/Akt, enhanced early myocyte survival and improved cardiac function ^[11]. (Full-length Tβ4, not the fragment.)

Wound healing. Topical or intraperitoneal thymosin beta-4 in a rat full-thickness wound model increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction and raised collagen deposition and angiogenesis; 10 picograms stimulated keratinocyte migration two-to-three-fold ^[12]. (Full-length Tβ4.)

Human safety (full-length protein). In a randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 was given intravenously to 40 healthy volunteers — single dose then daily for 14 days at 42, 140, 420 or 1260 mg — with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, no serious adverse events, and dose-proportional pharmacokinetics ^[9]. This used full-length Tβ4, not the TB-500 fragment.

Animal dose-response. In rats with embolic stroke, thymosin beta-4 at 2 and 12 mg/kg improved neurological function; 18 mg/kg gave no significant benefit — a non-monotonic result ^[7].

Field-level review. A 2026 Sports Medicine narrative review concluded that unapproved peptides including TB-500 show favorable animal tissue-repair outcomes but that rigorous human safety data are scarce and these compounds operate largely outside regulatory oversight ^[6].

Reported effects, cautions & safety

The cautions for TB-500 are specific and well-documented:

• Identity gap. Most efficacy data are from full-length Tβ4; no completed controlled clinical trials of the TB-500 fragment exist for any indication ^[8].
• Tumor/angiogenesis signal. Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor blood-vessel growth; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[8].
• Mixed preclinical results. In dystrophin-deficient mice, chronic Tβ4 increased regenerating fibers but did not improve muscle strength, cardiac function or fibrosis; systemic Tβ4 failed to reduce myocardial ischemia-reperfusion injury in a porcine study ^[8].
• Non-monotonic dosing. In the rat stroke study, 18 mg/kg helped less than 12 mg/kg — higher is not necessarily better, undermining community loading rationales ^[7].
• Regulatory. WADA prohibits TB-500 in sport; it is a prescription medicine in some jurisdictions and has appeared as a doping agent in racehorses ^[6].

No community-anecdote reports are compiled in this digest's source material for TB-500; cautions above are drawn from the cited literature.

Where it fits in recovery research

TB-500 occupies a specific niche on this digest: a compound whose mechanism — actin regulation driving cell migration — is well described at the protein level, but whose evidence as the actual fragment sold is unestablished in controlled human trials ^[8]. Where BPC-157 leads with angiogenesis and has three small human pilots, TB-500's story is fundamentally thymosin beta-4's story, borrowed. That makes it the clearest case study in why this field rewards careful reading. See how it lines up on the comparison page.